CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01%
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CureVac NV
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Capital Expenditures
-€55.2m
CAGR 3-Years
-5%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Capital Expenditures
-€705.5m
CAGR 3-Years
-102%
CAGR 5-Years
-60%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Capital Expenditures
-€2.5m
CAGR 3-Years
60%
CAGR 5-Years
-1%
CAGR 10-Years
9%
Immatics NV
NASDAQ:IMTX
Capital Expenditures
-€31m
CAGR 3-Years
-60%
CAGR 5-Years
-128%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Capital Expenditures
-€33.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
Capital Expenditures
-€21.2m
CAGR 3-Years
-228%
CAGR 5-Years
-82%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is CureVac NV's Capital Expenditures?
Capital Expenditures
-55.2m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Capital Expenditures amounts to -55.2m EUR.

What is CureVac NV's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-30%

Over the last year, the Capital Expenditures growth was 41%. The average annual Capital Expenditures growth rates for CureVac NV have been -5% over the past three years , -30% over the past five years .

Back to Top